James A. Graf, Interim CFO at NKGen Biotech, Inc. (NKGN), bought 670 shares at $3.19 ($2K) on 2023-12-04, disclosed to the SEC on 2023-12-05.
Open-market purchase of $2k NKGN by Interim CFO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Several strong factors at once. The rarest rating we give.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.35 | 220 | $737 | 33.9% |
| 2 | $3.19 | 450 | $1K | 66.1% |
| Total | $3.24 avg | 670 | $2K | 100% |
| Filing → |
| GFOR | BUY | 2021-05-25 | $13K | — | Filing → |
| EAGL | BUY | 2019-03-01 | $10K | — | Filing → |
| EAGL | BUY | 2012-05-08 | $4 | — | Filing → |